Humacyte, Inc. (HUMA)
0.4112
-0.06
(-12.47%)
USD |
NASDAQ |
Oct 30, 16:00
0.42
+0.01
(+2.14%)
After-Hours: 20:00
Humacyte Price to Book Value : 3.654 for Oct. 30, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 3.654 |
| October 29, 2026 | 4.175 |
| October 28, 2026 | 4.178 |
| October 27, 2026 | 3.966 |
| October 26, 2026 | 3.560 |
| October 23, 2026 | 3.869 |
| October 22, 2026 | 3.671 |
| October 21, 2026 | 3.654 |
| October 20, 2026 | 3.608 |
| October 19, 2026 | 3.564 |
| October 16, 2026 | 3.812 |
| October 15, 2026 | 3.906 |
| October 14, 2026 | 3.147 |
| October 13, 2026 | 3.189 |
| October 12, 2026 | 3.462 |
| October 09, 2026 | 3.602 |
| October 08, 2026 | 3.973 |
| October 07, 2026 | 4.197 |
| October 06, 2026 | 4.248 |
| October 05, 2026 | 4.443 |
| October 02, 2026 | 4.634 |
| October 01, 2026 | 4.469 |
| September 30, 2026 | 4.601 |
| September 29, 2026 | 4.734 |
| September 28, 2026 | 4.863 |
| Date | Value |
|---|---|
| September 25, 2026 | 4.952 |
| September 24, 2026 | 5.054 |
| September 23, 2026 | 5.027 |
| September 22, 2026 | 5.179 |
| September 21, 2026 | 5.243 |
| September 18, 2026 | 5.204 |
| September 17, 2026 | 5.111 |
| September 16, 2026 | 5.065 |
| September 15, 2026 | 4.902 |
| September 14, 2026 | 4.985 |
| September 11, 2026 | 5.044 |
| September 10, 2026 | 5.040 |
| September 09, 2026 | 5.145 |
| September 08, 2026 | 5.287 |
| September 04, 2026 | 5.376 |
| September 03, 2026 | 5.296 |
| September 02, 2026 | 5.302 |
| September 01, 2026 | 5.069 |
| August 31, 2026 | 5.344 |
| August 28, 2026 | 5.777 |
| August 27, 2026 | 6.156 |
| August 26, 2026 | 6.057 |
| August 25, 2026 | 6.231 |
| August 24, 2026 | 5.885 |
| August 21, 2026 | 5.707 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Amgen, Inc. | 21.55 |
| Altimmune, Inc. | 0.8366 |
| Protalix Biotherapeutics, Inc. | 2.922 |
| Taysha Gene Therapies, Inc. | 3.469 |
| Agenus, Inc. | -- |
Price to Book Value Related Metrics
| PS Ratio | 37.67 |
| PEG Ratio | -0.1158 |
| Price | 0.4112 |
| Earnings Yield | -119.1% |
| Market Cap | 114.23M |
| PEGY Ratio | -0.1158 |